A simple pill can soon cure diabetes: Scientists

Researchers at Mount Sinai are developing a revolutionary pill using harmine, a DYRK1A inhibitor, to regenerate insulin-producing beta cells in the pancreas. Harmine alone tripled beta cell mass, and combined with a GLP-1 agonist like Ozempic, increased it by 700%. The team discovered that alpha cells could potentially be transformed into beta cells, offering a new source for insulin production.

Will GLP-1 pills change diabetes treatment?

wn.com - 26/Feb 05:20

With the U.S. Food and Drug Administration (FDA) recently approving GLP-1 drug Wegovy in pill form for use in weight loss and fighting obesity, the...

Will GLP-1 pills change diabetes treatment?

wn.com - 26/Feb 05:20

With the U.S. Food and Drug Administration (FDA) recently approving GLP-1 drug Wegovy in pill form for use in weight loss and fighting obesity, the...

Risk for Nonscarring Hair Loss Increased in Association With GLP-1 Receptor Agonist Use

drugs.com - 18/Feb 16:02

WEDNESDAY, Feb. 18, 2026 -- The risk for nonscarring hair loss (NSHL) is increased in association with glucagon-like peptide-1 receptor agonist (GLP-1...

Risk for Nonscarring Hair Loss Increased in Association With GLP-1 Receptor Agonist Use

drugs.com - 18/Feb 16:02

WEDNESDAY, Feb. 18, 2026 -- The risk for nonscarring hair loss (NSHL) is increased in association with glucagon-like peptide-1 receptor agonist (GLP-1...

“Cyborg” pancreas? New implant could help lab-grown cells treat diabetes

knowridge.com - 22/Feb 00:35

Scientists are developing a futuristic approach to treating diabetes that sounds like science fiction but may one day become reality. Researchers at...

WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)

wn.com - 18:44

This is the first positive Phase 3 trial of a HIF-2 alpha inhibitor in combination with a multi-targeted tyrosine kinase inhibitor, the first for...

WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)

wn.com - 18:44

This is the first positive Phase 3 trial of a HIF-2 alpha inhibitor in combination with a multi-targeted tyrosine kinase inhibitor, the first for...

Rubriques :

A simple pill can soon cure diabetes: Scientists

Articles similaires

Will GLP-1 pills change diabetes treatment?

Will GLP-1 pills change diabetes treatment?

Risk for Nonscarring Hair Loss Increased in Association With GLP-1 Receptor Agonist Use

Risk for Nonscarring Hair Loss Increased in Association With GLP-1 Receptor Agonist Use

“Cyborg” pancreas? New implant could help lab-grown cells treat diabetes

WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)

WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)

Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China

Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China

Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China

Les derniers communiqués